Alwyn Heerden - MultiPlan VP Devel
| MPLN Stock | USD 10.03 0.98 8.90% |
Insider
Alwyn Heerden is VP Devel of MultiPlan
| Address | 115 Fifth Avenue, New York, NY, United States, 10003 |
| Phone | 212 780 2000 |
| Web | https://www.multiplan.us |
MultiPlan Management Efficiency
The company has return on total asset (ROA) of 0.0139 % which means that it generated a profit of $0.0139 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9882) %, meaning that it created substantial loss on money invested by shareholders. MultiPlan's management efficiency ratios could be used to measure how well MultiPlan manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of October 2024, Return On Capital Employed is likely to grow to 0.04, while Return On Tangible Assets are likely to drop (0.15). At this time, MultiPlan's Total Current Assets are very stable compared to the past year. As of the 24th of October 2024, Non Currrent Assets Other is likely to grow to about 7.1 M, while Net Tangible Assets are likely to drop (5.9 B).Similar Executives
| Showing other executives | INSIDER Age | ||
| Jaffry Mohammed | Sharecare | 48 | |
| Kristi Lane | Healthcare Triangle | N/A | |
| Shibu Kizhakevilayil | Healthcare Triangle | 52 | |
| Jeffrey Arnold | Sharecare | 54 | |
| Susan Neo | FOXO Technologies | N/A | |
| Thyagarajan Ramachandran | Healthcare Triangle | 48 | |
| Steven Sobak | EUDA Health Holdings | 78 | |
| Jon Hunt | Heartbeam | 68 | |
| Walter Brouwer | Sharecare | N/A | |
| David Kronfeld | Definitive Healthcare Corp | N/A | |
| LaChoenda Rosales | Nutex Health | N/A | |
| Steven Sabes | FOXO Technologies | 56 | |
| Jim Grauel | FOXO Technologies | N/A | |
| Richard Booth | Definitive Healthcare Corp | 55 | |
| Jon Bates | Nutex Health | 54 | |
| Carlos Solo | CareMax | 45 | |
| Harsha Panyadahundi | Sharecare | N/A | |
| Suresh Venkatachari | Healthcare Triangle | 57 | |
| Regla Wuilchrist | CareMax | N/A | |
| FACC MD | Heartbeam | 65 | |
| Lakshmanan Kannappan | Healthcare Triangle | 57 | |
Management Performance
| Return On Equity | -0.99 | ||||
| Return On Asset | 0.0139 |
MultiPlan Leadership Team
Elected by the shareholders, the MultiPlan's board of directors comprises two types of representatives: MultiPlan inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MultiPlan. The board's role is to monitor MultiPlan's management team and ensure that shareholders' interests are well served. MultiPlan's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MultiPlan's outside directors are responsible for providing unbiased perspectives on the board's policies.
| P Philbrick, Independent Director | ||
| William Veghte, Independent Director | ||
| Mark Tabak, Chairman of the Board, Chief Executive Officer | ||
| Bruce Singleton, Senior Strategy | ||
| Danielle Dupre, Chief Officer | ||
| Lucas CFA, Senior Relations | ||
| Tara ONeil, General Counsel | ||
| Pamela Walker, Director Communications | ||
| Jerome III, Executive COO | ||
| Carol Nutter, Senior Officer | ||
| Stephen Sofoul, Senior Services | ||
| Melissa Humphrey, Senior Communications | ||
| Andrea Rowe, Senior Product | ||
| Sean Crandell, Senior Economics | ||
| Christopher Dorn, Senior Services | ||
| Doug Garis, Executive CFO | ||
| Jeffrey Doctoroff, Senior Vice President General Counsel, Secretary | ||
| Jim Head, Chief Financial Officer, Executive Vice President | ||
| Andrew Cone, Senior Officer | ||
| Richard Clarke, Independent Director | ||
| C Harris, Independent Director | ||
| Alwyn Heerdan, Vice Development | ||
| Gerald Kozel, Senior Officer | ||
| Dale White, President, Chief Executive Officer, Director | ||
| Paul Galant, President - New Markets | ||
| Michael Kim, Senior Vice President, Chief Information Officer | ||
| David Redmond, Chief Financial Officer, Executive Vice President | ||
| Travis Dalton, CEO President | ||
| Paul Emery, Independent Director | ||
| Alwyn Heerden, VP Devel | ||
| Susan Mohler, VP Management | ||
| Michael Klein, Director | ||
| Julie Klapstein, Independent Director | ||
| Glenn August, Independent Director | ||
| James Head, Chief Financial Officer, Executive Vice President | ||
| Allen Thorpe, Lead Independent Director | ||
| Anthony Colaluca, Independent Director | ||
| Derek ReisLarson, Senior Services |
MultiPlan Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MultiPlan a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.99 | ||||
| Return On Asset | 0.0139 | ||||
| Profit Margin | (1.23) % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 4.66 B | ||||
| Shares Outstanding | 16.14 M | ||||
| Shares Owned By Institutions | 100.00 % | ||||
| Number Of Shares Shorted | 441.77 K | ||||
| Price To Earning | 9.87 X | ||||
| Price To Book | 0.27 X |
Pair Trading with MultiPlan
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if MultiPlan position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MultiPlan will appreciate offsetting losses from the drop in the long position's value.Moving together with MultiPlan Stock
Moving against MultiPlan Stock
| 0.82 | TFX | Teleflex Incorporated | PairCorr |
| 0.8 | MMSI | Merit Medical Systems | PairCorr |
| 0.7 | DOCS | Doximity | PairCorr |
| 0.62 | EVH | Evolent Health | PairCorr |
| 0.5 | VEEV | Veeva Systems Class | PairCorr |
The ability to find closely correlated positions to MultiPlan could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace MultiPlan when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back MultiPlan - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling MultiPlan to buy it.
The correlation of MultiPlan is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as MultiPlan moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if MultiPlan moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for MultiPlan can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MultiPlan. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in MultiPlan Stock, please use our How to Invest in MultiPlan guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MultiPlan. If investors know MultiPlan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MultiPlan listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share (72.40) | Revenue Per Share 59.002 | Quarterly Revenue Growth (0.02) | Return On Assets 0.0139 |
The market value of MultiPlan is measured differently than its book value, which is the value of MultiPlan that is recorded on the company's balance sheet. Investors also form their own opinion of MultiPlan's value that differs from its market value or its book value, called intrinsic value, which is MultiPlan's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MultiPlan's market value can be influenced by many factors that don't directly affect MultiPlan's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MultiPlan's value and its price as these two are different measures arrived at by different means. Investors typically determine if MultiPlan is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MultiPlan's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.